Quantification of AR, ERα, ERβ, and PGR in human prostate tissues
| The expression levels are displayed as a ratio between the target gene and a reference gene (RPLP0) to correct for variation in the amounts of RNA as well as of that specific marker for epithelial cells (KRT18) and/or stroma cells (VIM) according to the cell-type specificity expression of the target gene. RPLP0, KRT18, and VIM denote acidic ribosomal phosphoprotein P0, cytokeratin 18, and vimentin. . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|
| Samples . | Normala (mean ± SD) . | Clinically localized (mean ± SD) . | Hormone-refractoryb (mean ± SD) . | P c . | ||||
| AR:RPLP0 | 1.00 ± 0.15 | 1.15 ± 0.54 | 7.38 ± 7.23 | <0.001 | ||||
| AR:KRT18 | 1.00 ± 0.15 | 1.00 ± 0.38 | 12.31 ± 13.1 | <0.001 | ||||
| ERα:RPLP0 | 1.00 ± 0.20 | 0.71 ± 0.52 | 0.58 ± 0.54 | NSd (P = 0.16) | ||||
| ERα:VIM | 1.00 ± 0.38 | 1.29 ± 0.65 | 0.59 ± 0.45 | 0.02 | ||||
| ERβ:RPLP0 | 1.00 ± 0.20 | 0.47 ± 0.46 | 0.38 ± 0.45 | 0.02 | ||||
| ERβ:KRT18 | 1.00 ± 0.31 | 0.38 ± 0.39 | 0.62 ± 0.64 | NS (P = 0.07) | ||||
| ERβ:VIM | 1.00 ± 0.23 | 1.16 ± 1.00 | 0.52 ± 0.48 | NS (P = 0.23) | ||||
| PGR:RPLP0 | 1.00 ± 0.74 | 0.42 ± 0.38 | 1.30 ± 1.25 | NS (P = 0.18) | ||||
| PGR:VIM | 1.00 ± 1.00 | 0.90 ± 0.65 | 1.90 ± 2.00 | NS (P = 0.67) | ||||
| The expression levels are displayed as a ratio between the target gene and a reference gene (RPLP0) to correct for variation in the amounts of RNA as well as of that specific marker for epithelial cells (KRT18) and/or stroma cells (VIM) according to the cell-type specificity expression of the target gene. RPLP0, KRT18, and VIM denote acidic ribosomal phosphoprotein P0, cytokeratin 18, and vimentin. . | . | . | . | . | ||||
|---|---|---|---|---|---|---|---|---|
| Samples . | Normala (mean ± SD) . | Clinically localized (mean ± SD) . | Hormone-refractoryb (mean ± SD) . | P c . | ||||
| AR:RPLP0 | 1.00 ± 0.15 | 1.15 ± 0.54 | 7.38 ± 7.23 | <0.001 | ||||
| AR:KRT18 | 1.00 ± 0.15 | 1.00 ± 0.38 | 12.31 ± 13.1 | <0.001 | ||||
| ERα:RPLP0 | 1.00 ± 0.20 | 0.71 ± 0.52 | 0.58 ± 0.54 | NSd (P = 0.16) | ||||
| ERα:VIM | 1.00 ± 0.38 | 1.29 ± 0.65 | 0.59 ± 0.45 | 0.02 | ||||
| ERβ:RPLP0 | 1.00 ± 0.20 | 0.47 ± 0.46 | 0.38 ± 0.45 | 0.02 | ||||
| ERβ:KRT18 | 1.00 ± 0.31 | 0.38 ± 0.39 | 0.62 ± 0.64 | NS (P = 0.07) | ||||
| ERβ:VIM | 1.00 ± 0.23 | 1.16 ± 1.00 | 0.52 ± 0.48 | NS (P = 0.23) | ||||
| PGR:RPLP0 | 1.00 ± 0.74 | 0.42 ± 0.38 | 1.30 ± 1.25 | NS (P = 0.18) | ||||
| PGR:VIM | 1.00 ± 1.00 | 0.90 ± 0.65 | 1.90 ± 2.00 | NS (P = 0.67) | ||||
The ratios for each type of analysis have been normalized in such a manner that the mean ratio of the normal prostate samples equals a value of 1.
The values for T101 were excluded from the calculation because they are inconsistent with those for the hormone refractory tumors.
Ps were calculated by the Kruscal-Wallis test or the Mann-Whitney U test.
NS, not significant.